REGENXBIO

267 articles about REGENXBIO

• REGENXBIO to Present at Upcoming Investor Conferences - Nov 23, 2020

  11/23/2020

  REGENXBIO Inc., a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, announced it will present at the following December investor conferences, which will each be held in a virtual meeting format:

• REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2020 Annual Meeting

  11/10/2020

   REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ®  Technology Platform, today announced that two oral presentations will be presented at the American Academy Ophthalmology (AAO) 2020 Annual Meeting, ta

• REGENXBIO to Present at Upcoming Investor Conferences - Nov 05, 2020

  11/5/2020

  REGENXBIO Inc., a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, announced it will present at the following November investor conferences, which will each be held in a virtual meeting format:

• REGENXBIO Reports Third Quarter 2020 Financial Results and Operational Highlights

  11/4/2020

  REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced financial results for the quarter ended September 30, 2020, and recent operational highlights.

• 

  How COVID-19 is Catalyzing a Better, More Efficient Biopharma Environment

  11/4/2020

  The COVID-19 pandemic changed the biopharma industry and the world irrevocably. The challenges will reverberate even after the pandemic ends, according to panelists at the Cell and Gene Meeting on the Mesa in mid-October.

• REGENXBIO To Host Conference Call on November 4 to Discuss Third Quarter 2020 Financial Results and Recent Operational Highlights

  10/28/2020

   REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Wednesday, November 4, 2020, at 4:30 p.m. ET

• REGENXBIO to Receive $80.0 Million Milestone Payment from Novartis AG

  10/27/2020

  Zolgensma is the first gene therapy based on REGENXBIO's NAV® Technology Platform approved by the FDA and other regulatory authorities

• REGENXBIO Announces Continued Progress and Expansion of Clinical Development Program for RGX-121 for the Treatment of Mucopolysaccharidosis Type II (MPS II)

  9/30/2020

  Ongoing Phase I/II trial to enroll up to 6 additional patients in Cohort 2 while planning for next steps in program; further trial updates expected by the end of 2020

• REGENXBIO to Participate in Upcoming Investor Conferences - Sep 25, 2020

  9/25/2020

  REGENXBIO Inc., announced it will participate in the following upcoming investor conferences, which will each be held in a virtual meeting format:

• REGENXBIO Announces Dosing of First Patient in Phase II AAVIATE™ Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery

  9/9/2020

  Targeted, in-office suprachoroidal delivery of RGX-314 using the SCS Microinjector® may provide additional administration options for patients with wet AMD

• REGENXBIO to Participate in Upcoming Investor Conferences - Sep 02, 2020

  9/2/2020

  REGENXBIO Inc., a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, announced it will participate in the following September investor conferences, which will each be held in a virtual meeting format:

• REGENXBIO Announces FDA Clearance of IND for Phase II Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

  8/25/2020

  Company expects to initiate enrollment in the Phase II trial, ALTITUDE, in the second half of 2020 to evaluate the targeted, in-office suprachoroidal delivery of RGX-314

• 

  Clinical Catch-Up: August 3-7

  8/10/2020

  It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.

• REGENXBIO Reports Second Quarter 2020 Financial Results and Operational Highlights

  8/6/2020

  RGX-314 subretinal delivery pivotal program for wet AMD to initiate by end of 2020; positive interim update from Cohorts 4 and 5 at one year in Phase I/IIa trial recently announced

• REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update and Program Updates for RGX-314 for the Treatment of Wet AMD

  8/4/2020

  REGENXBIO Inc., a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, reported positive one year data from patients in Cohorts 4 and 5 of the Phase I/IIa trial of RGX-314 for the treatment of wet age-related macular degeneration.

• REGENXBIO To Host Conference Call on August 6 to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights

  7/30/2020

  REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Thursday, August 6, 2020, at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2020, and recent operational highlights.

• REGENXBIO Provides Update on Progress of Clinical Programs for Rare Genetic Neurodegenerative Diseases

  7/8/2020

  RGX-111 and RGX-121 continue to be well-tolerated in patients with MPS I and MPS II following one-time intracisternal administration

• REGENXBIO to Present at the Raymond James Human Health Innovation Conference

  6/10/2020

  REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology Platform, today announced it will present at the Raymond James Human Health Innovation Conference on Wednesday, June 17, 2020 , at 3:00 p.m. E

• REGENXBIO Reports First Quarter 2020 Financial Results and Operational Highlights

  5/7/2020

  Positive long-term and interim data update from RGX-314 Phase I/IIa trial for wet AMD recently announced

• REGENXBIO To Host Conference Call on May 7 to Discuss First Quarter 2020 Financial Results and Recent Operational Highlights

  4/30/2020

  REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Thursday, May 7, 2020, at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31